<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02296411</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-05993AB1-02</org_study_id>
    <secondary_id>2014‐001442‐16</secondary_id>
    <nct_id>NCT02296411</nct_id>
  </id_info>
  <brief_title>Efficacy of LAMA Added to ICS in Treatment of Asthma</brief_title>
  <acronym>ELITRA</acronym>
  <official_title>A Multicentre, Randomised, Double-blind, Placebo-controlled, 2-way Cross-over Study to Evaluate the Efficacy and Safety of CHF 5259 (Glycopyrrolate Bromide) pMDI on Top of QVAR® pMDI for the Treatment of Patients With Uncontrolled Asthma on Low-Medium Dose of Inhaled Corticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the superiority of the glycopyrrolate bromide (CHF
      5259 pMDI) versus placebo on top of QVAR® pMDI, in terms of lung functions parameters, as
      well as to assess its safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 (Forced Expiratory Volume in the first second) AUC0-12h (Area Under the Curve for 0-12 hours) normalised by time on Day 42</measure>
    <time_frame>Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (Peak of Forced Expiratory Volume in the first second ) on Day 42</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events and Adverse Drug reactions</measure>
    <time_frame>Up to 17 Weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CHF 5259 12.5 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 5259 12.5 µg: 2 inhalations bid (50µg daily dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5259 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CHF 5259 placebo: 2 inhalations bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5259 12.5 µg</intervention_name>
    <description>comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks</description>
    <arm_group_label>CHF 5259 12.5 µg</arm_group_label>
    <other_name>glycopyrrolate bromide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5259 placebo</intervention_name>
    <description>comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks</description>
    <arm_group_label>CHF 5259 placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of asthma ≥ 5 years and diagnosed before 40 years old

          -  Uncontrolled asthma on low-medium doses of Inhaled CorticoSteroid (ICS) with ACQ
             (Asthma Control Questionnaire) ≥1.5

          -  Pre-bronchodilator FEV1 ≥40% and &lt;90% of their predicted normal value

          -  Positive reversibility test

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)

          -  Patients treated for asthma exacerbation in the 4 weeks prior to study entry

          -  Patients who are in therapy for gastroesophageal reflux disease

          -  Patients who have a clinically significant cardiovascular condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0107</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0106</name>
      <address>
        <city>Sevlievo</city>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0101</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0109</name>
      <address>
        <city>Sofia</city>
        <zip>1336</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0108</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0102</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0103</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0201</name>
      <address>
        <city>Berlin</city>
        <zip>D-12165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0203</name>
      <address>
        <city>Leipzig</city>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0202</name>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0206</name>
      <address>
        <city>Magdeburg</city>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0207</name>
      <address>
        <city>Radebeul</city>
        <zip>01445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0208</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0306</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0301</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0304</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0303</name>
      <address>
        <city>Pordenone</city>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0404</name>
      <address>
        <city>Assen</city>
        <zip>9401 RK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0405</name>
      <address>
        <city>Helmond</city>
        <zip>5707 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0501</name>
      <address>
        <city>Bialystok</city>
        <zip>15-010</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0502</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0503</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0507</name>
      <address>
        <city>Krakow</city>
        <zip>30-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0504</name>
      <address>
        <city>Krakow</city>
        <zip>31-011</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0512</name>
      <address>
        <city>Lodz</city>
        <zip>90-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0510</name>
      <address>
        <city>Lodz</city>
        <zip>90-252</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0505</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-310</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 0506</name>
      <address>
        <city>Zgierz</city>
        <zip>95-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001442-16</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2014</study_first_submitted>
  <study_first_submitted_qc>November 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma, Anticholinergics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

